<DOC>
	<DOCNO>NCT01125566</DOCNO>
	<brief_summary>To investigate efficacy safety BIBW 2992 combination vinorelbine i.v . chemotherapy treatment patient HER2-overexpressing , metastatic breast cancer , fail one prior trastuzumab ( HerceptinÂ® ) treatment</brief_summary>
	<brief_title>LUX-Breast 1 : BIBW 2992 ( Afatinib ) HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis HER2overexpression breast cancer Stage IV metastatic disease Must progress one prior trastuzumab treatment one prior trastuzumab base therapy regimen ( either adjuvant firstline ) Must receive anthracycline and/or taxane base chemotherapy adjuvant treatment breast cancer firstline treatment metastatic breast cancer Must ( archive ) tumour tissue sample available central reassessment HER2status At least one measurable lesion accord RECIST 1.1 . ECOG score 0 1 . Exclusion criterion : Prior treatment EGFR/HER2targeted small molecule antibody trastuzumab Prior treatment vinorelbine Known preexist interstitial lung disease Active brain metastasis History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification 3 , unstable angina poorly control arrhythmia . Myocardial infarction within 6 month prior randomisation . Cardiac leave ventricular function rest ejection fraction le 50 % . Patients unable comply protocol . Any contraindication therapy vinorelbine trastuzumab . Known hypersensitivity BIBW 2992 excipients trial drug . Use investigational drug within 4 week randomisation . Inadequate hepatic , renal haematologic organ function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>